Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company advancing novel therapies for immunological, inflammatory, and oncological conditions with significant unmet needs. This dedicated news hub provides investors and industry professionals with essential updates on therapeutic developments, strategic partnerships, and clinical progress.
Access timely announcements including clinical trial milestones, regulatory submissions, and research collaborations. Our curated collection ensures you stay informed about pipeline candidates targeting complex conditions like pulmonary arterial hypertension and inflammatory bowel diseases.
Bookmark this page for centralized access to Gossamer Bio's latest press releases and financial communications. Regularly updated with verified information, this resource supports informed decision-making without speculative commentary.
Gossamer Bio (Nasdaq: GOSS), a clinical-stage biopharmaceutical firm, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee of Gossamer's Board approved non-qualified stock options for a new non-executive employee, effective June 5, 2024. The grant includes options to purchase up to 170,000 shares at an exercise price of $0.57 per share, equivalent to the closing price on the Nasdaq Global Select Market on that date. These options have a ten-year term and will vest over four years: 25% after one year, with the remaining shares vesting in 36 monthly installments. These inducement awards aim to attract new talent under Gossamer's 2023 Employment Inducement Incentive Award Plan.
Gossamer Bio (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, will present updated data on seralutinib at the American Thoracic Society 2024 International Conference from May 17-22 in San Diego.
The presentations will include interim results from the Phase 1B and Phase 2 TORREY open-label extension study in pulmonary arterial hypertension (PAH) and additional data on circulating biomarkers, inflammation, and fibrosis. The main presentation will be on May 19 by Dr. Olivier Sitbon.
Gossamer Bio, Inc. (NASDAQ: GOSS) granted non-executive employees stock options under the 2023 Inducement Plan. The options allow the purchase of up to 323,000 shares at $0.755 per share, vesting over four years. This grant aims to incentivize and retain new employees in accordance with Nasdaq rules.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced its first quarter 2024 financial results and business update. The company reported $396 million in cash, pro forma for a $160 million reimbursement payment and debt repayment. They are collaborating with Chiesi for seralutinib development and co-commercialization. The PROSERA Phase 3 study for PAH is ongoing, with top-line results expected in Q4 2025. A registrational Phase 3 study for PH-ILD is set to begin in mid-2025. TORREY Phase 2 PAH results were published in Lancet Respiratory Medicine, with additional data to be presented at ATS in May.
Gossamer Bio and Chiesi Group have announced a global collaboration to develop and commercialize Seralutinib for pulmonary hypertension. Gossamer will receive development reimbursement and milestones payments, leading the US commercialization activities. Chiesi obtains exclusive ex-US commercial rights with Gossamer receiving royalties on net sales. A Phase 3 trial of Seralutinib in PH-ILD is planned for mid-2025.
Gossamer Bio, Inc. announced the publication of the TORREY Phase 2 study results in the Lancet Respiratory Medicine, showcasing the positive impact of seralutinib in treating pulmonary arterial hypertension. The study demonstrated significant improvements in pulmonary vascular resistance and other key disease measures. This milestone sets the stage for the Phase 3 PROSERA Study, highlighting the potential of seralutinib to enhance the quality of life for PAH patients.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
